ZYME•benzinga•
Zymeworks Reveals NMPA Approval Of Zanidatamab In China For Adults With Previously Treated, Unresectable Or Metastatic HER2-high Expression (IHC3+) Biliary Tract Cancer, Says $20M Milestone Payment To Be Received From BeOne Medicines
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 30, 2025 by benzinga